Research of diagnostic significance of lymph nodes micrometastasis by OSNA for pStage II colorectal cancer.

Research of diagnostic significance of lymph nodes micrometastasis by OSNA for pStage II colorectal cancer. - Research of diagnostic significance of lymph nodes micrometastasis by OSNA for pStage II colorectal cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037532

Enrollment

3000

Registered

2019-08-01

Start date

2019-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <OSNA installed facility> Patients 20 years old or older Patients diagnosed with cStage I-III colorectal cancer Patients who is to carry out OSNA Patients who have not offered a refuse to optout <OSNA non-installed facility> Patients 20 years old or older Patients diagnosed with cStage I-III colorectal cancer Lymph nodes collected at the time of surgery is cryopreserved and available Patients who obtained written consent

Exclusion criteria

Exclusion criteria: <OSNA installed facility> Patients who lack the ability to agree Patients who receive neoadjuvant chemotherapy Active double cancer (synchronous double cancer/Multiple cancer and metachronous double cancer/multiple cancer with disease-free survival of 5 years or less, but excluding carcinoma in situ that is judged to be cured by local treatment Patients who died or relapsed within 60 days after the operation Patients who is judged to be ineligible to participate in the study by the research principal doctor or co-investigator <OSNA non-installed facility> Patients who lack the ability to agree Patients who receive neoadjuvant chemotherapy Active double cancer (synchronous double cancer/Multiple cancer and metachronous double cancer/multiple cancer with disease-free survival of 5 years or less, but excluding carcinoma in situ that is judged to be cured by local treatment Patients who died or relapsed within 60 days after the operation Patients who is judged to be ineligible to participate in the study by the research principal doctor or co-investigator

Design outcomes

Primary

Measure	Time frame
3 year recurrence free survival rate	—

Secondary

Measure	Time frame
5 year recurrence free survival rate Association between clinicopathological factors and diagnosis of OSNA Association with postoperative adjuvant chemotherapy	—

Countries

Japan

Contacts

Public ContactMamoru Uemura

Osaka University Department of Gastroenterology

muemura@gesurg.med.osaka-u.ac.jp0668793251

Outcome results